Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Navicixizumab (OMP-305B83) is a bispecific anti- VEGF and anti- DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3] .
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Navicixizumab (OMP-305B83) is a bispecific anti- VEGF and anti- DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3] . |
Molecular Weight | N/A |
CAS No. | 1638338-43-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Navicixizumab 1638338-43-8 inhibitor inhibit